Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):26-30. doi: 10.3928/15428877-20091230-05.

Intravitreal dexamethasone for diabetic macular edema: a pilot study.

Author information

  • 1Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.

Abstract

BACKGROUND AND OBJECTIVE:

To determine the response and safety profile of intravitreal dexamethasone in treating diabetic macular edema.

PATIENTS AND METHODS:

In this prospective pilot study, 12 eyes of 12 patients with diabetic macular edema were randomized to receive a single injection of 0.4 mg (n = 6) or 0.8 mg (n = 6) of intravitreal dexamethasone. The outcome measures were changes in best-corrected visual acuity and central foveal thickness on optical coherence tomography. Side effects were monitored.

RESULTS:

The 3-month results were reported. In both dosage groups, there were transient improvements in best-corrected visual acuity and central foveal thickness, but the changes were not significant at any time point (best-corrected visual acuity: P > or = 0.14; central foveal thickness: P > or = .08). No significant side effects were observed, except one eye developed a peak intraocular pressure of greater than 21 mm Hg.

CONCLUSION:

A single injection of intravitreal dexamethasone (0.4 or 0.8 mg) did not have significant beneficial effects on diabetic macular edema within 3 months from injection in this small pilot study.

Copyright 2010, SLACK Incorporated.

PMID:
20128566
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk